Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP (LONN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
281.8(c) 285.3(c) 288.9(c) 288.4(c) 287.8 Last
266 130 245 905 274 190 219 080 142 040 Volume
-0.35% +1.24% +1.26% -0.17% -0.21% Change
More quotes
Financials (CHF)
Sales 2018 6 017 M
EBIT 2018 1 143 M
Net income 2018 734 M
Debt 2018 3 569 M
Yield 2018 1,08%
Sales 2019 6 390 M
EBIT 2019 1 281 M
Net income 2019 874 M
Debt 2019 3 028 M
Yield 2019 1,24%
P/E ratio 2018 30,58
P/E ratio 2019 25,33
EV / Sales2018 4,17x
EV / Sales2019 3,84x
Capitalization 21 514 M
More Financials
Company
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products.It operates through the Pharma&Biotech and Specialty Ingredients segemnts.The Pharma&Biotech segment deals with the supply of pharmaceutical ingredients and biopharmaceuticals as well as research and... 
More about the company
Surperformance© ratings of Lonza Group
Trading Rating : Investor Rating :
More Ratings
Latest news on LONZA GROUP
07/16LONZA : Consumer Product Ingredients Expands Its Distribution Relationship with ..
PU
07/13LONZA : Exosomics Siena Launches Exosome-Based Liquid Biopsy Solutions for the S..
PU
07/11LONZA : Federal Contracts Awarded by Federal Agencies in Texas (July 11)
AQ
07/11LONZA : Publishes Pre-Announcement for Half-Year Results 2018
AQ
07/10LONZA : MILITARY $5.93 Million Federal Contract Awarded to Arch Chemicals
AQ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/09Lonza Publishes Pre-Announcement for Half-Year Results 2018
TE
07/09LONZA : Publishes Pre-Announcement for Half-Year Results 2018
AQ
07/06LONZA : Launches New Bioscience Website
AQ
07/02LONZA : Launches New Bioscience Website
PU
More news
Sector news : Biotechnology & Medical Research - NEC
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on LONZA GROUP 
LONZA GROUP - 04/20
Technically solid
BUY
LONZA GROUP - 01/24
The stock forcefully approaches new pivot levels
BUY
More Strategies
Latest Tweets
07/13$LONN Group AG The risk of captive manufacturing and high client bargaining .. 
07/07Empty Capsules: 2018 Global Procurement Market Intelligence Report - Top 5 Su.. 
07/02Lonza : Launches New Bioscience Website  
06/28Investigators are still looking for the cause of yesterday's fire at Lonza. H..
1
06/20Lonza : Emphasizes Importance of Preventing Microbial Contamination Following.. 
More tweets
Qtime:57
News from SeekingAlpha
06/03Orgenesis, Inc. - Overlooked Stock In The Gene Therapy Contract Development W.. 
05/04Lonza Group AG 2018 Q1 - Results - Earnings Call Slides 
04/30The Best Way To Invest In Pharma And Biotech? 
01/31Lonza Group AG ADR 2017 Q4 - Results - Earnings Call Slides 
01/31Lonza Group AG reports FY results 
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | LONN | CH0013841017 | 4-Traders
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 295  CHF
Spread / Average Target 2,3%
EPS Revisions
Managers
NameTitle
Richard Ridinger Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP9.53%21 465
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147
ALNYLAM PHARMACEUTICALS, INC.-15.41%10 803